Recursion Pharmaceuticals Raises $200 Million in Public Offering to Advance Drug Discovery Technology
Salt Lake City-based TechBio company, Recursion Pharmaceuticals, Inc. (Recursion), recently announced the pricing of its underwritten public offering of Class A common stock. The company aims to raise approximately $200 million through the sale of 30,769,230 shares, priced at $6.50 per share. Recursion has also provided the underwriters a 30-day option to purchase an additional 4,615,384 shares.
Recursion Pharmaceuticals has gained prominence in the clinical stage through its innovative approach to drug discovery. By leveraging cutting-edge technology and decoding complex biological data, the company aims to industrialize and accelerate the drug discovery process. This latest funding round will provide Recursion with the necessary financial resources to further advance its technology and pipeline of potential therapies.
The expectation of $200 million in gross proceeds from this public offering will significantly bolster Recursion’s efforts to discover and develop new drugs across various therapeutic areas. The successful completion of this offering will enable the company to invest further in its state-of-the-art technology platform, automation capabilities, and computational tools.
The funds raised will also support the expansion of Recursion’s talented team of scientists, engineers, and data analysts. With a robust workforce, the company will have the capacity to accelerate its drug discovery programs and scale its operations. Moreover, Recursion aims to enhance its collaborations with academic institutions, biotech partners, and pharmaceutical companies to drive innovation and foster strategic alliances within the industry.
Recursion Pharmaceuticals has pioneered an integrative approach that combines artificial intelligence (AI), machine learning, and automation to analyze vast amounts of biological data and generate actionable insights. This approach has proven successful in identifying potential therapeutic targets and expediting the discovery of novel drug candidates. By industrializing these processes, Recursion aims to revolutionize the field of drug discovery with the potential to bring life-changing treatments to patients faster and more efficiently.
The closing of this offering, scheduled for June 28, 2024, is contingent upon customary closing conditions. Recursion Pharmaceuticals is poised to make significant progress in advancing its drug discovery technology and accelerating the development of potential life-saving therapies. The successful completion of this public offering will undoubtedly position the company as a key player in the biopharmaceutical industry.
Comments